| 1 |
34983084 | Eplerenone repurposing in management of chorioretinopathy: Mechanism, nanomedicine-based delivery applications and future trends. | 2022 Jun |
2 |
| 2 |
35582468 | GRK5 is an essential co-repressor of the cardiac mineralocorticoid receptor and is selectively induced by finerenone. | 2022 Apr 26 |
2 |
| 3 |
35607563 | Bilateral Adrenalectomy in a Patient With Refractory Primary Aldosteronism Due to Adrenal Hyperplasia. | 2022 Apr |
1 |
| 4 |
32473789 | Aldosterone receptor antagonists. | 2021 Jun |
1 |
| 5 |
32661269 | Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease. | 2021 Feb |
2 |
| 6 |
32799671 | The role of aldosterone inhibitors in cardiac ischemia-reperfusion injury. | 2021 Jan |
1 |
| 7 |
33055188 | The Mineralocorticoid Receptor Antagonist Eplerenone Suppresses Interstitial Fibrosis in Subcutaneous Adipose Tissue in Patients With Type 2 Diabetes. | 2021 Jan |
1 |
| 8 |
33179798 | Role of mineralocorticoid receptor antagonists in kidney diseases. | 2021 May |
2 |
| 9 |
33904521 | Striatin genotype-based, mineralocorticoid receptor antagonist-driven clinical trial: study rationale and design. | 2021 Jun 1 |
1 |
| 10 |
33995571 | Eplerenone as a treatment for resistant hypertension in pregnancy. | 2021 Mar |
1 |
| 11 |
34205363 | Impact of Aldosterone on the Failing Myocardium: Insights from Mitochondria and Adrenergic Receptors Signaling and Function. | 2021 Jun 19 |
1 |
| 12 |
34233330 | The Forgotten Antiproteinuric Properties of Diuretics. | 2021 |
1 |
| 13 |
34272676 | Effects of mineralocorticoid receptor antagonist eplerenone on cardiac sympathetic nerve activity and left ventricular remodeling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction. | 2021 Jul 16 |
1 |
| 14 |
34461222 | Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy. | 2021 Oct |
1 |
| 15 |
34595995 | An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension. | 2021 Oct |
1 |
| 16 |
34790127 | Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease. | 2021 |
1 |
| 17 |
31079056 | Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience. | 2020 Feb |
1 |
| 18 |
32128854 | Aldosterone and the mineralocorticoid receptor in renal injury: A potential therapeutic target in feline chronic kidney disease. | 2020 May |
2 |
| 19 |
32973172 | Aldosterone up-regulates voltage-gated potassium currents and NKCC1 protein membrane fractions. | 2020 Sep 24 |
1 |
| 20 |
33082868 | Diagnostic efficacy of intravascular ultrasound combined with Gd2O3-EPL contrast agent for patients with atherosclerosis. | 2020 Dec |
2 |
| 21 |
30444201 | The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy. | 2019 |
2 |
| 22 |
30678854 | Mineralocorticoid Receptor Antagonists. | 2019 |
1 |
| 23 |
31014765 | Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials. | 2019 Feb |
2 |
| 24 |
31183945 | Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial (MIRAD trial). | 2019 Oct |
2 |
| 25 |
31522177 | Mineralocorticoid Receptor Antagonists Stimulate Human Hair Growth ex vivo. | 2019 |
1 |
| 26 |
29622372 | Treatment of Unruptured Cerebral Aneurysms with the Mineralocorticoid Receptor Blocker Eplerenone-Pilot Study. | 2018 Aug |
1 |
| 27 |
29659888 | Randomized, Placebo-Controlled Trial to Evaluate Effects of Eplerenone on Metabolic and Inflammatory Indices in HIV. | 2018 Jun 1 |
1 |
| 28 |
30056252 | Mineralocorticoid receptor blockade improves arginine transport and nitric oxide generation through modulation of cationic amino acid transporter-1 in endothelial cells. | 2018 Nov 1 |
1 |
| 29 |
30275698 | Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses. | 2018 |
2 |
| 30 |
30280597 | Periarterial fat from two human vascular beds is not a source of aldosterone to promote vasoconstriction. | 2018 Dec 1 |
1 |
| 31 |
28011746 | The Pharmacology of Autonomic Failure: From Hypotension to Hypertension. | 2017 Jan |
2 |
| 32 |
28515448 | Involvement Of Vascular Aldosterone Synthase In Phosphate-Induced Osteogenic Transformation Of Vascular Smooth Muscle Cells. | 2017 May 17 |
2 |
| 33 |
28634268 | 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. | 2017 Jul |
1 |
| 34 |
28824029 | Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF). | 2017 Dec 25 |
2 |
| 35 |
29121365 | Irvine-Gass Macular Edema Responding to the Combination of Oral Mineralocorticoid-Receptor Antagonist With Dexamethasone Drops. | 2017 Nov 1 |
1 |
| 36 |
29274772 | Evidence for the use of mineralocorticoid receptor antagonists in the treatment of coronary artery disease and post-angioplasty restenosis. | 2017 Dec 21 |
1 |
| 37 |
26639352 | Acute effect of mineralocorticoid receptor antagonism on vascular function in healthy older adults. | 2016 Jan |
2 |
| 38 |
26644241 | Mineralocorticoid Receptor Activation Contributes to the Supine Hypertension of Autonomic Failure. | 2016 Feb |
2 |
| 39 |
27115525 | Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD? | 2016 Apr |
1 |
| 40 |
27503378 | MicroRNA-34b/c inhibits aldosterone-induced vascular smooth muscle cell calcification via a SATB2/Runx2 pathway. | 2016 Dec |
2 |
| 41 |
27664711 | Mineralocorticoid Receptor Antagonists-A New Sprinkle of Salt and Youth. | 2016 Oct |
1 |
| 42 |
27680666 | Caveolin 1 Modulates Aldosterone-Mediated Pathways of Glucose and Lipid Homeostasis. | 2016 Sep 28 |
1 |
| 43 |
28956026 | Mineralocorticoid Receptor, A Promising Target for Improving Management of Low Back Pain by Epidural Steroid Injections. | 2016 |
2 |
| 44 |
25458175 | Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. | 2015 Jan |
1 |
| 45 |
25564371 | Aldosterone promotes cardiac endothelial cell proliferation in vivo. | 2015 Jan 6 |
1 |
| 46 |
25646700 | Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis. | 2015 Sep |
1 |
| 47 |
26213109 | Pharmacological treatment of aldosterone excess. | 2015 Oct |
1 |
| 48 |
26404746 | Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone. | 2015 Dec 1 |
2 |
| 49 |
26404747 | Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF). | 2015 Dec 1 |
2 |
| 50 |
26404748 | Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. | 2015 Dec 1 |
4 |